Allogene Therapeutics
Ton Schumacher, PhD serves as Senior Member at the Netherlands Cancer Institute in Amsterdam and Professor of Immunotechnology at Leiden University Medical Center. He completed his PhD at The Netherlands Cancer Institute where he studied the interactions of MHC class I molecules with antigenic peptides in the laboratory of Dr. Hidde Ploegh. After completing a postdoctoral fellowship in Dr. Ploegh’s lab at the Massachusetts Institute of Technology, he joined the group of Dr. Peter Kim at the Whitehead Institute in Cambridge, Mass. Ton later returned to the Netherlands Cancer Institute to study the development of tumor-specific T cell immunity through biotechnological approaches. Ton is a recipient of, among others, the Amsterdam Inventor Award, Queen Wilhelmina Cancer Research Award, San Salvatore Award, Meyenburg Cancer Research Award, and William B. Coley Award, and is founder of three biotechnology companies in the area of immuno-oncology.
This person is not in the org chart
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.